Pharmacogenetics, race, and ethnicity: Social identities and individualized medical care

Morris W. Foster, Richard R Sharp, John J. Mulvihill

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Social categories such as race and ethnicity have long been used in interpreting patient symptoms, diagnosing disease, and predicting therapeutic response. DNA-based diagnostic tests and pharmacogenetic screens could make these uses of social categories largely irrelevant by allowing clinicians to base diagnosis and treatment decisions on the unique genetic features of individual patients. Despite this attractive vision of individualized care, however, social categories are likely to continue playing a significant role in the coming era of genetic medicine. Current uses of social categories in pharmacogenetic research, for example, illustrate how drug development and marketing will perpetuate the use of social categories such as race and ethnicity. Those uses may unintentionally blunt the precision of genetic technologies and pose new threats to socially identifiable populations. These implications suggest the need for greater caution in using social categories as indicators for specific tests or therapies and for federal legislation to protect against discriminatory uses of individuals' genetic information. In addition, more precise social classifications than those presently in use may allow us to realize the full potential of DNA-based technologies, thus minimizing social disparities in health care. Those more precise social classifications should reflect extended patient pedigrees and not the self-reported claims of racial and/or ethnic affiliation.

Original languageEnglish (US)
Pages (from-to)232-238
Number of pages7
JournalTherapeutic Drug Monitoring
Volume23
Issue number3
DOIs
StatePublished - Jun 2001

Fingerprint

Social Identification
Pharmacogenetics
Health care
DNA
Healthcare Disparities
Medicine
Technology
Marketing
Pedigree
Legislation
Routine Diagnostic Tests
Therapeutics
Pharmaceutical Preparations
Research
Population

Keywords

  • Ethics
  • Ethnicity
  • Pharmacogenetics
  • Race
  • Research methods

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Pharmacogenetics, race, and ethnicity : Social identities and individualized medical care. / Foster, Morris W.; Sharp, Richard R; Mulvihill, John J.

In: Therapeutic Drug Monitoring, Vol. 23, No. 3, 06.2001, p. 232-238.

Research output: Contribution to journalArticle

@article{c789746d56fc426fb26e56766fb08730,
title = "Pharmacogenetics, race, and ethnicity: Social identities and individualized medical care",
abstract = "Social categories such as race and ethnicity have long been used in interpreting patient symptoms, diagnosing disease, and predicting therapeutic response. DNA-based diagnostic tests and pharmacogenetic screens could make these uses of social categories largely irrelevant by allowing clinicians to base diagnosis and treatment decisions on the unique genetic features of individual patients. Despite this attractive vision of individualized care, however, social categories are likely to continue playing a significant role in the coming era of genetic medicine. Current uses of social categories in pharmacogenetic research, for example, illustrate how drug development and marketing will perpetuate the use of social categories such as race and ethnicity. Those uses may unintentionally blunt the precision of genetic technologies and pose new threats to socially identifiable populations. These implications suggest the need for greater caution in using social categories as indicators for specific tests or therapies and for federal legislation to protect against discriminatory uses of individuals' genetic information. In addition, more precise social classifications than those presently in use may allow us to realize the full potential of DNA-based technologies, thus minimizing social disparities in health care. Those more precise social classifications should reflect extended patient pedigrees and not the self-reported claims of racial and/or ethnic affiliation.",
keywords = "Ethics, Ethnicity, Pharmacogenetics, Race, Research methods",
author = "Foster, {Morris W.} and Sharp, {Richard R} and Mulvihill, {John J.}",
year = "2001",
month = "6",
doi = "10.1097/00007691-200106000-00009",
language = "English (US)",
volume = "23",
pages = "232--238",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Pharmacogenetics, race, and ethnicity

T2 - Social identities and individualized medical care

AU - Foster, Morris W.

AU - Sharp, Richard R

AU - Mulvihill, John J.

PY - 2001/6

Y1 - 2001/6

N2 - Social categories such as race and ethnicity have long been used in interpreting patient symptoms, diagnosing disease, and predicting therapeutic response. DNA-based diagnostic tests and pharmacogenetic screens could make these uses of social categories largely irrelevant by allowing clinicians to base diagnosis and treatment decisions on the unique genetic features of individual patients. Despite this attractive vision of individualized care, however, social categories are likely to continue playing a significant role in the coming era of genetic medicine. Current uses of social categories in pharmacogenetic research, for example, illustrate how drug development and marketing will perpetuate the use of social categories such as race and ethnicity. Those uses may unintentionally blunt the precision of genetic technologies and pose new threats to socially identifiable populations. These implications suggest the need for greater caution in using social categories as indicators for specific tests or therapies and for federal legislation to protect against discriminatory uses of individuals' genetic information. In addition, more precise social classifications than those presently in use may allow us to realize the full potential of DNA-based technologies, thus minimizing social disparities in health care. Those more precise social classifications should reflect extended patient pedigrees and not the self-reported claims of racial and/or ethnic affiliation.

AB - Social categories such as race and ethnicity have long been used in interpreting patient symptoms, diagnosing disease, and predicting therapeutic response. DNA-based diagnostic tests and pharmacogenetic screens could make these uses of social categories largely irrelevant by allowing clinicians to base diagnosis and treatment decisions on the unique genetic features of individual patients. Despite this attractive vision of individualized care, however, social categories are likely to continue playing a significant role in the coming era of genetic medicine. Current uses of social categories in pharmacogenetic research, for example, illustrate how drug development and marketing will perpetuate the use of social categories such as race and ethnicity. Those uses may unintentionally blunt the precision of genetic technologies and pose new threats to socially identifiable populations. These implications suggest the need for greater caution in using social categories as indicators for specific tests or therapies and for federal legislation to protect against discriminatory uses of individuals' genetic information. In addition, more precise social classifications than those presently in use may allow us to realize the full potential of DNA-based technologies, thus minimizing social disparities in health care. Those more precise social classifications should reflect extended patient pedigrees and not the self-reported claims of racial and/or ethnic affiliation.

KW - Ethics

KW - Ethnicity

KW - Pharmacogenetics

KW - Race

KW - Research methods

UR - http://www.scopus.com/inward/record.url?scp=0034997236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034997236&partnerID=8YFLogxK

U2 - 10.1097/00007691-200106000-00009

DO - 10.1097/00007691-200106000-00009

M3 - Article

C2 - 11360031

AN - SCOPUS:0034997236

VL - 23

SP - 232

EP - 238

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 3

ER -